Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab

Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab

Objectives Disease-modifying therapies (DMTs) can slow disease progression in multiple sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) progression among newly diagnosed people with MS in relation to the first DMT received.Design and setting A cohort study using d...

Full description

Bibliographic Details
Main Authors: Andrius Kavaliunas, Tomas Olsson, Jan Hillert, Chantelle Murley, Kristina Alexanderson, Emilie Friberg, Hanna Gyllensten, Korinna Karampampa
Format: Article
Language:English
Published: BMJ Publishing Group 2023-05-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/5/e067516.full

Internet

https://bmjopen.bmj.com/content/13/5/e067516.full

Similar Items